| Feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid Health Maintenance Organization. | |
| | |
MedLine Citation:
|
PMID: 16225924 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To assess the feasibility of an automatic switch of a large number of patients with glaucoma or suspicion of glaucoma from latanoprost to bimatoprost, and to compare the efficacy of the 2 prostaglandin analogs before and after the switch. DESIGN: Retrospective nonrandomized comparison. PARTICIPANTS: Forty-three thousand four hundred forty-one California patients and 538 patients at one Southern California clinical facility of a nationwide prepaid health maintenance organization (HMO) who were on either prostaglandin between March 2002 and December 2003 (21 months). METHODS: Beginning in April 2002, patients on latanoprost were systemically switched to bimatoprost by the HMO pharmacy service after obtaining approval from the entire ophthalmology staff. PART 1: computerized dispensing records of California patients were retrieved. PART 2: medical records of patients at one clinical facility were reviewed. MAIN OUTCOME MEASURES: Rates of switching or switching back from one prostaglandin to another, intraocular pressure (IOP) control, and intolerability. RESULTS: PART 1: 17847 patients initially received latanoprost. Of them, 84.8% were switched from latanoprost to bimatoprost, and 13.0% were switched back to latanoprost. Twenty-five thousand five hundred ninety-four patients were started on bimatoprost without previous experience with latanoprost. Of them, 8.6% were later switched to latanoprost use instead. Patients who had previous experience with latanoprost had a statistically significantly higher rate of switching back to latanoprost after a period of bimatoprost use when compared with those who had no prior experience with latanoprost (13.0% vs. 8.6%, respectively; P<0.0001). PART 2: 309 patients were switched from latanoprost to bimatoprost. The mean IOP reduction of 0.51+/-2.77 mmHg (95% confidence interval, 0.20-0.82) after the switch was statistically significant (P = 0.001). Forty-one patients (13.3%) had a decrease of >3 mmHg of IOP. The statistical significance of the IOP reduction after the switch remains in the monotherapy group (P = 0.005) but not in the multitherapy group (P = 0.058). Thirty-three patients (10.7%) who were switched from latanoprost to bimatoprost discontinued bimatoprost and resumed latanoprost. CONCLUSION: A systematic pharmacy-level switch from latanoprost to bimatoprost in a nationwide HMO achieved a high switch rate, with little switching back. There was a small but statistically significant reduction in mean IOP after the switch. An appreciable proportion of patients switched had a clinically significant reduction of IOP. |
| | |
Authors:
|
Simon K Law; Brian J Song; Ervin Fang; Joseph Caprioli |
Related Documents
:
|
1754654 - Discriminating schizophrenics from borderline patients: study with the holtzman inkblot... 7530014 - Dialyzer permeability for low-molecular-weight proteins. comparison between polysulfone... 18180684 - Deposition of lipid, protein, and secretory phospholipase a2 on hydrophilic contact len... 1857314 - Urticarial contact dermatitis in food handlers. 14525994 - Spheniscins, avian beta-defensins in preserved stomach contents of the king penguin, ap... 11447394 - A voluntary registry for peanut and tree nut allergy: characteristics of the first 5149... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't Date: 2005-10-12 |
Journal Detail:
|
Title: Ophthalmology Volume: 112 ISSN: 1549-4713 ISO Abbreviation: Ophthalmology Publication Date: 2005 Dec |
Date Detail:
|
Created Date: 2005-12-05 Completed Date: 2005-12-13 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7802443 Medline TA: Ophthalmology Country: United States |
Other Details:
|
Languages: eng Pagination: 2123-30 Citation Subset: IM |
Affiliation:
|
Jules Stein Eye Institute, University of California, Los Angeles, California 90095, USA. law@jsei.ucla.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Aged, 80 and over Amides Antihypertensive Agents / adverse effects, therapeutic use* California / epidemiology Child Child, Preschool Cloprostenol / analogs & derivatives Feasibility Studies Female Glaucoma, Open-Angle / drug therapy*, physiopathology Health Maintenance Organizations / statistics & numerical data* Humans Intraocular Pressure / drug effects* Lipids / adverse effects, therapeutic use* Male Middle Aged Ocular Hypertension / drug therapy, physiopathology Pharmaceutical Preparations / supply & distribution Prostaglandins F, Synthetic / adverse effects, therapeutic use* Retrospective Studies Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Amides; 0/Antihypertensive Agents; 0/Lipids; 0/Pharmaceutical Preparations; 0/Prostaglandins F, Synthetic; 0/bimatoprost; 130209-82-4/latanoprost; 40665-92-7/Cloprostenol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Novel NR2E3 mutations (R104Q, R334G) associated with a mild form of enhanced S-cone syndrome demonst...
Next Document: Benefits and side effects of bandage soft contact lens application after LASIK: a prospective random...